ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS
Updated: Jun 3
Addex Therapeutics Limited is a clinical-stage biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neurological disorders. The company is listed on the NASDAQ under the ticker symbol "ADXN" and has a market capitalization of over $200 million.
Addex Therapeutics was founded in 2002 and is headquartered in Geneva, Switzerland. The company's proprietary technology platform, allosteric modulation, is designed to target receptors and enzymes that are involved in the regulation of the nervous system. By targeting these receptors and enzymes, Addex Therapeutics is able to develop drugs that have the potential to treat a range of neurological disorders, including Parkinson's disease, epilepsy, and schizophrenia.
One of the key strengths of Addex Therapeutics is its focus on innovation and technology. The company's allosteric modulation platform is a unique and powerful tool for the development of new drugs. The platform allows the company to identify and target specific receptors and enzymes, which can lead to the development of more effective and safer drugs.
Another key strength of Addex Therapeutics is its pipeline of innovative drug candidates. The company has several drug candidates in clinical development, including dipraglurant for the treatment of Parkinson's disease and ADX71149 for the treatment of epilepsy. These drug candidates have shown promise in early clinical trials, and the company is actively working to advance them through the clinical development process.
Addex Therapeutics has also demonstrated a commitment to collaboration and partnerships. The company has established partnerships with other biotechnology companies and academic institutions to advance its research and development programs. For example, Addex Therapeutics has a collaboration agreement with Janssen Pharmaceuticals to develop new drugs for the treatment of schizophrenia.
In recent years, Addex Therapeutics has also been actively exploring new investment opportunities. The company has made several strategic investments in other biotechnology companies, which helps to diversify its portfolio and provide exposure to new and innovative technologies. This focus on innovation and new investment opportunities helps to ensure that Addex Therapeutics remains at the forefront of the biopharmaceutical industry.
Addex Therapeutics is a company with a strong focus on innovation and technology. With a pipeline of innovative drug candidates, a commitment to collaboration and partnerships, and a focus on new investment opportunities, Addex Therapeutics is well-positioned to continue to make a meaningful impact in the field of biopharmaceuticals.